• This partnership combines innovative technology and expertise in clinical applications to produce automated and multiplexed solutions to advance the diagnosis of autoimmune diseases.
• This partnership expands access to the specialized autoimmune IVD market, valued at $2 billion with MosaiQ.
• Market introduction is planned for the second half of 2023; Autoimmune IVDs are generally faster and cheaper to market than blood transfusion-related IVDs due to different regulatory requirements.